[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin.]
[L04AA27, fingolimod, Daunorubicin may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daunorubicin.]
[M04AB02, sulfinpyrazone, Daunorubicin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Daunorubicin.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Daunorubicin.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Daunorubicin.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Daunorubicin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Tetracaine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Daunorubicin.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be increased when combined with Daunorubicin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Daunorubicin.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Daunorubicin.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Daunorubicin.]
[P01AB02, tinidazole, Daunorubicin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Daunorubicin.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Daunorubicin.]
[N06AX05, trazodone, The metabolism of Trazodone can be increased when combined with Daunorubicin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Daunorubicin.]
[N05CD05, triazolam, The metabolism of Triazolam can be increased when combined with Daunorubicin.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Daunorubicin.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mometasone.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Daunorubicin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belimumab.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Daunorubicin.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Daunorubicin.]
[J05AP03, boceprevir, The metabolism of Boceprevir can be increased when combined with Daunorubicin.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be increased when combined with Daunorubicin.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Daunorubicin.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Daunorubicin.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be increased when combined with Daunorubicin.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be increased when combined with Daunorubicin.]
[C08DA01, verapamil, The metabolism of Verapamil can be increased when combined with Daunorubicin.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Daunorubicin.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Daunorubicin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Daunorubicin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Daunorubicin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Daunorubicin.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Daunorubicin.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Daunorubicin.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Daunorubicin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be decreased when combined with Daunorubicin.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Daunorubicin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Daunorubicin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin.]
[C07AB03, atenolol, Atenolol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Daunorubicin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be increased when combined with Daunorubicin.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Daunorubicin.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Daunorubicin.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Daunorubicin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Daunorubicin.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Daunorubicin.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Daunorubicin.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Daunorubicin.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be increased when combined with Daunorubicin.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Daunorubicin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Daunorubicin.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Daunorubicin.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Daunorubicin.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Daunorubicin.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Daunorubicin.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Daunorubicin.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Daunorubicin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, Daunorubicin may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzocaine.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Daunorubicin.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Daunorubicin.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Daunorubicin may increase the myelosuppressive activities of Lipegfilgrastim.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Daunorubicin.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Daunorubicin.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Daunorubicin.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Daunorubicin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Daunorubicin.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Daunorubicin.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Daunorubicin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Daunorubicin.]
[N07XX08, tafamidis, The serum concentration of Daunorubicin can be increased when it is combined with Tafamidis.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Daunorubicin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Daunorubicin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Daunorubicin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Daunorubicin.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Daunorubicin.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Daunorubicin.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Daunorubicin.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Daunorubicin.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Daunorubicin.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be increased when combined with Daunorubicin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Daunorubicin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Daunorubicin.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Daunorubicin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mepolizumab.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Daunorubicin.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Daunorubicin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Daunorubicin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Daunorubicin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Daunorubicin.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Daunorubicin.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Daunorubicin.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Daunorubicin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Bupivacaine.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05BE01, buspirone, The metabolism of Buspirone can be increased when combined with Daunorubicin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Daunorubicin.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Daunorubicin.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Daunorubicin.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Daunorubicin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Daunorubicin.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Daunorubicin.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be increased when combined with Daunorubicin.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Daunorubicin.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be increased when combined with Daunorubicin.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Daunorubicin.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Daunorubicin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Daunorubicin.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Daunorubicin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Daunorubicin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Daunorubicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Daunorubicin.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Daunorubicin.]
[J05AG03, efavirenz, Efavirenz may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Daunorubicin.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Daunorubicin.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Daunorubicin.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Daunorubicin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Capsaicin.]
[L02BB05, apalutamide, Apalutamide may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Daunorubicin.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Baricitinib.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Daunorubicin.]
[N03AX17, stiripentol, The excretion of Daunorubicin can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be increased when combined with Daunorubicin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Daunorubicin.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Daunorubicin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Chloroprocaine.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be increased when combined with Daunorubicin.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Daunorubicin.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Daunorubicin.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Daunorubicin.]
[J01FA09, clarithromycin, Daunorubicin may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Daunorubicin.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cloprednol.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Daunorubicin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Daunorubicin.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Daunorubicin.]
[J01DC04, cefaclor, Daunorubicin may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Daunorubicin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Daunorubicin.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Daunorubicin.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Daunorubicin.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Daunorubicin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Daunorubicin.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deflazacort.]
[L01FD01, trastuzumab, The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.]
[N02CC08, lasmiditan, The serum concentration of Daunorubicin can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Daunorubicin.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Daunorubicin.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be increased when combined with Daunorubicin.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Daunorubicin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Daunorubicin.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teprotumumab.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Daunorubicin.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be increased when combined with Daunorubicin.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Daunorubicin.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Daunorubicin.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Daunorubicin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Daunorubicin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Daunorubicin.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednidene.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Daunorubicin.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Daunorubicin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Daunorubicin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Daunorubicin.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be increased when combined with Daunorubicin.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Daunorubicin.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be increased when combined with Daunorubicin.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be increased when combined with Daunorubicin.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Relugolix can be increased when combined with Daunorubicin.]
[L01FD06, margetuximab, The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Daunorubicin.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Voclosporin.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Finasteride can be increased when combined with Daunorubicin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Daunorubicin.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Daunorubicin.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX73, sotorasib, The serum concentration of Daunorubicin can be increased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Daunorubicin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Daunorubicin.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Daunorubicin.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Anifrolumab.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be increased when combined with Daunorubicin.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Daunorubicin.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Daunorubicin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Daunorubicin can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Daunorubicin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Daunorubicin.]
[J02AC06, oteseconazole, The serum concentration of Daunorubicin can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be increased when combined with Daunorubicin.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Daunorubicin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Daunorubicin.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Daunorubicin is combined with Clozapine.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bimekizumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Daunorubicin.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be increased when combined with Daunorubicin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Telithromycin can be increased when combined with Daunorubicin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Daunorubicin.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Daunorubicin.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Daunorubicin.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Daunorubicin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Meprednisone.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be increased when combined with Daunorubicin.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Daunorubicin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin.]
[S01XA18, cyclosporine, Daunorubicin may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Modafinil can be increased when combined with Daunorubicin.]
[C10AA07, rosuvastatin, Daunorubicin may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Daunorubicin.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Daunorubicin.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Daunorubicin.]
[N06AX06, nefazodone, Daunorubicin may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Daunorubicin.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Daunorubicin.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Daunorubicin.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Daunorubicin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be increased when combined with Daunorubicin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Daunorubicin.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Daunorubicin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Daunorubicin.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Daunorubicin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cinchocaine.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Daunorubicin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Daunorubicin.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Daunorubicin.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C10AX09, ezetimibe, Daunorubicin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.]
[C04AE04, dihydroergocristine, Daunorubicin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Daunorubicin.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Daunorubicin.]
[J05AE08, atazanavir, Daunorubicin may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be increased when combined with Daunorubicin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Diphenhydramine.]
[B01AC07, dipyridamole, Daunorubicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Daunorubicin.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Daunorubicin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.]
[P03AA04, disulfiram, Daunorubicin may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Risperidone can be increased when combined with Daunorubicin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Daunorubicin.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be increased when combined with Daunorubicin.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Daunorubicin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Daunorubicin.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be increased when combined with Daunorubicin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be increased when combined with Daunorubicin.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be increased when combined with Daunorubicin.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Daunorubicin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Daunorubicin.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Temozolomide.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Daunorubicin.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Daunorubicin.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Daunorubicin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Daunorubicin.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be increased when combined with Daunorubicin.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Daunorubicin.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Daunorubicin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Daunorubicin.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Daunorubicin.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Daunorubicin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Daunorubicin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Daunorubicin.]
[R06AX12, terfenadine, Terfenadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Daunorubicin.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Daunorubicin.]
[C08CA02, felodipine, Daunorubicin may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Daunorubicin.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Daunorubicin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Daunorubicin.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Daunorubicin.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Daunorubicin.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Daunorubicin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Daunorubicin.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Daunorubicin.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Daunorubicin.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Daunorubicin.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Daunorubicin.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Daunorubicin.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be increased when combined with Daunorubicin.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be increased when combined with Daunorubicin.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A10BB07, glipizide, Daunorubicin may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Daunorubicin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Daunorubicin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Daunorubicin.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Daunorubicin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be increased when combined with Daunorubicin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be increased when combined with Daunorubicin.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Daunorubicin.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Daunorubicin.]
[C09CA01, losartan, Losartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Daunorubicin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Daunorubicin.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Daunorubicin.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Daunorubicin.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Daunorubicin.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be increased when combined with Daunorubicin.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Daunorubicin.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Hydroxyzine can be increased when combined with Daunorubicin.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Daunorubicin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Daunorubicin.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Paclitaxel poliglumex.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Daunorubicin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Articaine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Daunorubicin.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Daunorubicin.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Daunorubicin.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Daunorubicin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Daunorubicin.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Daunorubicin.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Daunorubicin.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Daunorubicin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Lidocaine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Daunorubicin.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Daunorubicin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Daunorubicin.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Daunorubicin.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Daunorubicin.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Daunorubicin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Daunorubicin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Daunorubicin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Melphalan.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Daunorubicin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Mepivacaine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be increased when combined with Daunorubicin.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Daunorubicin.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Daunorubicin.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Daunorubicin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Daunorubicin.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Methylprednisolone.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Daunorubicin.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Daunorubicin.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Daunorubicin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Daunorubicin.]
[G03XB01, mifepristone, Daunorubicin may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Daunorubicin.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daunorubicin.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Daunorubicin.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Daunorubicin.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Daunorubicin.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mycophenolic acid.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Daunorubicin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Daunorubicin.]
[M02AA12, naproxen, Daunorubicin may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daunorubicin.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Daunorubicin.]
[A10BX02, repaglinide, Daunorubicin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Daunorubicin.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Daunorubicin.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Daunorubicin can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Daunorubicin.]
[C08CA04, nicardipine, Nicardipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C08CA05, nifedipine, Daunorubicin may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be increased when combined with Daunorubicin.]
[C08CA08, nitrendipine, Daunorubicin may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Daunorubicin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be increased when combined with Daunorubicin.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Daunorubicin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Daunorubicin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Daunorubicin.]
[S02AA16, ofloxacin, Daunorubicin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Daunorubicin.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Daunorubicin.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be increased when combined with Daunorubicin.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Daunorubicin.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Daunorubicin.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daunorubicin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Daunorubicin.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Daunorubicin.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Daunorubicin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Daunorubicin.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Daunorubicin.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Daunorubicin.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Daunorubicin.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Daunorubicin.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be increased when combined with Daunorubicin.]
[C10AA08, pitavastatin, Daunorubicin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Daunorubicin.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Daunorubicin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine.]
[C10AB05, fenofibrate, Daunorubicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Daunorubicin.]
[C07AA05, propranolol, The metabolism of Propranolol can be increased when combined with Daunorubicin.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Daunorubicin.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Daunorubicin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Daunorubicin.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Daunorubicin.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be increased when combined with Daunorubicin.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Daunorubicin.]
[P01BC01, quinine, The metabolism of Quinine can be increased when combined with Daunorubicin.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Daunorubicin.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone butyrate.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Cytarabine.]
[L04AA27, fingolimod, Cytarabine may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cytarabine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cytarabine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Cytarabine.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Cytarabine.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cytarabine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Cytarabine is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Cytarabine.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Cytarabine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Cytarabine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Cytarabine.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Cytarabine.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Cytarabine.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Cytarabine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Cytarabine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Cytarabine.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Cytarabine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Cytarabine.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belimumab.]
[A10BH05, linagliptin, The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Cytarabine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belatacept.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Cytarabine.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cytarabine.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Cytarabine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Cytarabine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Cytarabine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Cytarabine.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Cytarabine.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Cytarabine.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cytarabine.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Cytarabine.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cytarabine.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Cytarabine is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cytarabine.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Cytarabine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cytarabine.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Cytarabine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cytarabine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Cytarabine.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Aldosterone.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cytarabine.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bendamustine.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Cytarabine.]
[L04AA29, tofacitinib, Cytarabine may increase the immunosuppressive activities of Tofacitinib.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Cytarabine.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Cytarabine.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cytarabine.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Everolimus.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzyl alcohol.]
[L03AA14, lipegfilgrastim, Cytarabine may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ibrutinib.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Cytarabine is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Cytarabine.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Cytarabine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Bezafibrate.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Cytarabine.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cytarabine.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Cytarabine is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Cytarabine.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Cytarabine.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Cytarabine.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Cytarabine.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Acipimox.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mepolizumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixekizumab.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Cytarabine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Brodalumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cytarabine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Cytarabine.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Cytarabine.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Cytarabine.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Vorinostat.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cytarabine.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cytarabine.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Cytarabine.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Cytarabine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Capsaicin.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Captopril.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Cytarabine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Cytarabine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Baricitinib.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Cytarabine.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cytarabine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Cytarabine.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Cytarabine.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ciprofibrate.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Siponimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ubidecarenone.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Cytarabine.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Risankizumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Upadacitinib.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Cytarabine.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cytarabine.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Cytarabine is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Cytarabine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Diroximel fumarate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Cytarabine.]
[C01BD07, dronedarone, The risk or severity of adverse effects can be increased when Dronedarone is combined with Cytarabine.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cytarabine.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cytarabine.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluprednidene.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Cytarabine is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Stepronin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Cytarabine.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Cytarabine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Cytarabine.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Choline salicylate is combined with Cytarabine.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Etofibrate.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fludarabine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Voclosporin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Cytarabine.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Formoterol is combined with Cytarabine.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Cytarabine.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Cytarabine.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Anifrolumab.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Cytarabine.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Cytarabine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Cytarabine can be increased when it is combined with Pacritinib.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Cytarabine is combined with Clozapine.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Cytarabine.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Cytarabine.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Cytarabine.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Cytarabine.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Cytarabine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cytarabine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Cytarabine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Cytarabine.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Cytarabine.]
[S01XA18, cyclosporine, Cytarabine may increase the immunosuppressive activities of Cyclosporine.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Rosuvastatin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fusidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Cytarabine.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Cytarabine.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Cytarabine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cytarabine.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cytarabine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Cytarabine.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Cytarabine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cinchocaine.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirarubicin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Difluocortolone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cytarabine.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Pramocaine.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Cytarabine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cytarabine.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Cytarabine.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Cytarabine.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Doxorubicin.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Cytarabine.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Cytarabine.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Cytarabine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Cytarabine.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Cytarabine.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Cytarabine.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Cytarabine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Cytarabine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Cytarabine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cytarabine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Iloprost.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fluvastatin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Cytarabine.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Cytarabine.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Cytarabine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Cytarabine.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Cytarabine.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cytarabine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Cytarabine.]
[J02AX01, flucytosine, The therapeutic efficacy of Flucytosine can be decreased when used in combination with Cytarabine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cytarabine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Cytarabine.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Cytarabine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cytarabine.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cytarabine.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Gemfibrozil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dasatinib.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Cytarabine.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Cytarabine.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Cytarabine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Cytarabine.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Cytarabine.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Cytarabine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Cytarabine.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Cytarabine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Cytarabine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Cytarabine.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Cytarabine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxyurea.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Cytarabine.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Cytarabine.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ifosfamide.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cytarabine.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cytarabine.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Articaine.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Cytarabine.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Cytarabine.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Cytarabine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Cytarabine.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Cytarabine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Cytarabine.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Cytarabine.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cytarabine.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Cytarabine.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Cytarabine.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Cytarabine.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Cytarabine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Lidocaine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Lomustine.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Cytarabine.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cytarabine.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Cytarabine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Cytarabine.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Cytarabine.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Cytarabine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Melphalan.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Mepivacaine.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Cytarabine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Cytarabine.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cytarabine.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Cytarabine.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cytarabine.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Cytarabine.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cytarabine.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Metoclopramide.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Cytarabine.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Cytarabine.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Minocycline.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cytarabine.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Amiodarone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mycophenolic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Raltegravir.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Cytarabine.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Cytarabine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cytarabine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Letrozole.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Cytarabine.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Cytarabine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Cytarabine.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Cytarabine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Cytarabine.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Norfloxacin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Cytarabine.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Rilonacept.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Cytarabine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Cytarabine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Cytarabine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Cytarabine.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Cytarabine.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cytarabine.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Phenformin is combined with Cytarabine.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Cytarabine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Cytarabine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Cytarabine.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Cytarabine.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Golimumab.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Cytarabine.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Cytarabine.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Cytarabine.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Cytarabine.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Cytarabine.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Pitavastatin.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Cytarabine.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Cytarabine.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Cytarabine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Prilocaine.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Cytarabine.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fenofibrate.]
[G03DA04, progesterone, The risk or severity of adverse effects can be increased when Progesterone is combined with Cytarabine.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Cytarabine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cytarabine.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Cytarabine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Cytarabine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Cytarabine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Cytarabine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Cytarabine.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cytarabine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone butyrate.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin.]
[L04AA27, fingolimod, Daunorubicin may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daunorubicin.]
[M04AB02, sulfinpyrazone, Daunorubicin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Daunorubicin.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Daunorubicin.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Daunorubicin.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Daunorubicin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Tetracaine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Daunorubicin.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be increased when combined with Daunorubicin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Daunorubicin.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Daunorubicin.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Daunorubicin.]
[P01AB02, tinidazole, Daunorubicin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Daunorubicin.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Daunorubicin.]
[N06AX05, trazodone, The metabolism of Trazodone can be increased when combined with Daunorubicin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Daunorubicin.]
[N05CD05, triazolam, The metabolism of Triazolam can be increased when combined with Daunorubicin.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Daunorubicin.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mometasone.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Daunorubicin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belimumab.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Daunorubicin.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Daunorubicin.]
[J05AP03, boceprevir, The metabolism of Boceprevir can be increased when combined with Daunorubicin.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be increased when combined with Daunorubicin.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Daunorubicin.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Daunorubicin.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be increased when combined with Daunorubicin.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be increased when combined with Daunorubicin.]
[C08DA01, verapamil, The metabolism of Verapamil can be increased when combined with Daunorubicin.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Daunorubicin.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Daunorubicin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Daunorubicin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Daunorubicin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Daunorubicin.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Daunorubicin.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Daunorubicin.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Daunorubicin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be decreased when combined with Daunorubicin.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Daunorubicin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Daunorubicin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin.]
[C07AB03, atenolol, Atenolol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Daunorubicin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be increased when combined with Daunorubicin.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Daunorubicin.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Daunorubicin.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Daunorubicin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Daunorubicin.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Daunorubicin.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Daunorubicin.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Daunorubicin.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be increased when combined with Daunorubicin.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Daunorubicin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Daunorubicin.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Daunorubicin.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Daunorubicin.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Daunorubicin.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Daunorubicin.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Daunorubicin.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Daunorubicin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, Daunorubicin may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzocaine.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Daunorubicin.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Daunorubicin.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Daunorubicin may increase the myelosuppressive activities of Lipegfilgrastim.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Daunorubicin.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Daunorubicin.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Daunorubicin.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Daunorubicin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Daunorubicin.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Daunorubicin.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Daunorubicin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Daunorubicin.]
[N07XX08, tafamidis, The serum concentration of Daunorubicin can be increased when it is combined with Tafamidis.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Daunorubicin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Daunorubicin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Daunorubicin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Daunorubicin.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Daunorubicin.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Daunorubicin.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Daunorubicin.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Daunorubicin.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Daunorubicin.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be increased when combined with Daunorubicin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Daunorubicin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Daunorubicin.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Daunorubicin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mepolizumab.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Daunorubicin.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Daunorubicin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Daunorubicin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Daunorubicin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Daunorubicin.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Daunorubicin.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Daunorubicin.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Daunorubicin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Bupivacaine.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N05BE01, buspirone, The metabolism of Buspirone can be increased when combined with Daunorubicin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Daunorubicin.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Daunorubicin.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Daunorubicin.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Daunorubicin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Daunorubicin.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Daunorubicin.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be increased when combined with Daunorubicin.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Daunorubicin.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be increased when combined with Daunorubicin.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Daunorubicin.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Daunorubicin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Daunorubicin.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Daunorubicin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Daunorubicin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Daunorubicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Daunorubicin.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Daunorubicin.]
[J05AG03, efavirenz, Efavirenz may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Daunorubicin.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Daunorubicin.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Daunorubicin.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Daunorubicin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Capsaicin.]
[L02BB05, apalutamide, Apalutamide may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Daunorubicin.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Baricitinib.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Daunorubicin.]
[N03AX17, stiripentol, The excretion of Daunorubicin can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be increased when combined with Daunorubicin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Daunorubicin.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Daunorubicin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Chloroprocaine.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be increased when combined with Daunorubicin.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Daunorubicin.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Daunorubicin.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Daunorubicin.]
[J01FA09, clarithromycin, Daunorubicin may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Daunorubicin.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Daunorubicin.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Daunorubicin.]
[J01DC04, cefaclor, Daunorubicin may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Daunorubicin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Daunorubicin.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Daunorubicin.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Daunorubicin.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Daunorubicin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Daunorubicin.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deflazacort.]
[L01FD01, trastuzumab, The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Daunorubicin.]
[N02CC08, lasmiditan, The serum concentration of Daunorubicin can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Daunorubicin.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Daunorubicin.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be increased when combined with Daunorubicin.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Daunorubicin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Daunorubicin.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teprotumumab.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Daunorubicin.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be increased when combined with Daunorubicin.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Daunorubicin.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Daunorubicin.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Daunorubicin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Daunorubicin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Daunorubicin.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednidene.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Daunorubicin.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Daunorubicin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Daunorubicin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Daunorubicin.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be increased when combined with Daunorubicin.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Daunorubicin.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be increased when combined with Daunorubicin.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be increased when combined with Daunorubicin.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Relugolix can be increased when combined with Daunorubicin.]
[L01FD06, margetuximab, The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Daunorubicin.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Voclosporin.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Finasteride can be increased when combined with Daunorubicin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Daunorubicin.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX73, sotorasib, The serum concentration of Daunorubicin can be increased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Daunorubicin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Daunorubicin.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Daunorubicin.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Anifrolumab.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be increased when combined with Daunorubicin.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Daunorubicin.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Daunorubicin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Daunorubicin can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Daunorubicin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Daunorubicin.]
[J02AC06, oteseconazole, The serum concentration of Daunorubicin can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be increased when combined with Daunorubicin.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Daunorubicin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Daunorubicin.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Daunorubicin is combined with Clozapine.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bimekizumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Daunorubicin.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be increased when combined with Daunorubicin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Telithromycin can be increased when combined with Daunorubicin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Daunorubicin.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Daunorubicin.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Daunorubicin.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Daunorubicin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Meprednisone.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be increased when combined with Daunorubicin.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Daunorubicin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin.]
[S01XA18, cyclosporine, Daunorubicin may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Modafinil can be increased when combined with Daunorubicin.]
[C10AA07, rosuvastatin, Daunorubicin may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Daunorubicin.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Daunorubicin.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Daunorubicin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Daunorubicin.]
[N06AX06, nefazodone, Daunorubicin may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Daunorubicin.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Daunorubicin.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Daunorubicin.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Daunorubicin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be increased when combined with Daunorubicin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Daunorubicin.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Daunorubicin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Daunorubicin.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Daunorubicin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cinchocaine.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Daunorubicin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Daunorubicin.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Daunorubicin.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C10AX09, ezetimibe, Daunorubicin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.]
[C04AE04, dihydroergocristine, Daunorubicin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Daunorubicin.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Daunorubicin.]
[J05AE08, atazanavir, Daunorubicin may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be increased when combined with Daunorubicin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Diphenhydramine.]
[B01AC07, dipyridamole, Daunorubicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Daunorubicin.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Daunorubicin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.]
[P03AA04, disulfiram, Daunorubicin may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Risperidone can be increased when combined with Daunorubicin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Daunorubicin.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be increased when combined with Daunorubicin.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Daunorubicin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Daunorubicin.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be increased when combined with Daunorubicin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be increased when combined with Daunorubicin.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be increased when combined with Daunorubicin.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Daunorubicin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Daunorubicin.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Temozolomide.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Daunorubicin.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Daunorubicin.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Daunorubicin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Daunorubicin.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be increased when combined with Daunorubicin.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Daunorubicin.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Daunorubicin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Daunorubicin.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Daunorubicin.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Daunorubicin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Daunorubicin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Daunorubicin.]
[R06AX12, terfenadine, Terfenadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Daunorubicin.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Daunorubicin.]
[C08CA02, felodipine, Daunorubicin may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Daunorubicin.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Daunorubicin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Daunorubicin.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Daunorubicin.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Daunorubicin.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Daunorubicin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Daunorubicin.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Daunorubicin.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Daunorubicin.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Daunorubicin.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Daunorubicin.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Daunorubicin.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be increased when combined with Daunorubicin.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be increased when combined with Daunorubicin.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A10BB07, glipizide, Daunorubicin may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Daunorubicin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Daunorubicin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Daunorubicin.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Daunorubicin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be increased when combined with Daunorubicin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be increased when combined with Daunorubicin.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Daunorubicin.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Daunorubicin.]
[C09CA01, losartan, Losartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Daunorubicin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Daunorubicin.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Daunorubicin.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Daunorubicin.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Daunorubicin.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be increased when combined with Daunorubicin.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Daunorubicin.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Hydroxyzine can be increased when combined with Daunorubicin.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Daunorubicin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Daunorubicin.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Daunorubicin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Articaine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Daunorubicin.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Daunorubicin.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Daunorubicin.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Daunorubicin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Daunorubicin.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Daunorubicin.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Daunorubicin.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Daunorubicin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Lidocaine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Daunorubicin.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Daunorubicin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Daunorubicin.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Daunorubicin.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Daunorubicin.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Daunorubicin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Daunorubicin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Daunorubicin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Melphalan.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Daunorubicin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Mepivacaine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be increased when combined with Daunorubicin.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Daunorubicin.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Daunorubicin.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Daunorubicin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Daunorubicin.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Methylprednisolone.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Daunorubicin.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Daunorubicin.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Daunorubicin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Daunorubicin.]
[G03XB01, mifepristone, Daunorubicin may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Daunorubicin.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daunorubicin.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Daunorubicin.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Daunorubicin.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Daunorubicin.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mycophenolic acid.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Daunorubicin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Daunorubicin.]
[M02AA12, naproxen, Daunorubicin may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daunorubicin.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Daunorubicin.]
[A10BX02, repaglinide, Daunorubicin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Daunorubicin.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Daunorubicin.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Daunorubicin can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Daunorubicin.]
[C08CA04, nicardipine, Nicardipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C08CA05, nifedipine, Daunorubicin may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be increased when combined with Daunorubicin.]
[C08CA08, nitrendipine, Daunorubicin may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Daunorubicin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be increased when combined with Daunorubicin.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Daunorubicin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Daunorubicin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Daunorubicin.]
[S02AA16, ofloxacin, Daunorubicin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Daunorubicin.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Daunorubicin.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be increased when combined with Daunorubicin.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Daunorubicin.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Daunorubicin.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daunorubicin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Daunorubicin.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Daunorubicin.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Daunorubicin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Daunorubicin.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Daunorubicin.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Daunorubicin.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Daunorubicin.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Daunorubicin.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be increased when combined with Daunorubicin.]
[C10AA08, pitavastatin, Daunorubicin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Daunorubicin.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Daunorubicin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine.]
[C10AB05, fenofibrate, Daunorubicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Daunorubicin.]
[C07AA05, propranolol, The metabolism of Propranolol can be increased when combined with Daunorubicin.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Daunorubicin.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Daunorubicin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Daunorubicin.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Daunorubicin.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be increased when combined with Daunorubicin.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Daunorubicin.]
[P01BC01, quinine, The metabolism of Quinine can be increased when combined with Daunorubicin.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Daunorubicin.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone butyrate.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Paclitaxel poliglumex.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Antilymphocyte immunoglobulin (horse).]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Cytarabine.]
[L04AA27, fingolimod, Cytarabine may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cytarabine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cytarabine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Cytarabine.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Cytarabine.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cytarabine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Cytarabine is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Cytarabine.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Cytarabine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Cytarabine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Cytarabine.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Cytarabine.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Cytarabine.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Cytarabine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Cytarabine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Cytarabine.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Cytarabine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Cytarabine.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belimumab.]
[A10BH05, linagliptin, The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Cytarabine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belatacept.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Cytarabine.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cytarabine.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Cytarabine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Cytarabine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Cytarabine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Cytarabine.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Cytarabine.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Cytarabine.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cytarabine.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Cytarabine.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cytarabine.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Cytarabine is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cytarabine.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Cytarabine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cytarabine.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Cytarabine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cytarabine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Cytarabine.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Aldosterone.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cytarabine.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bendamustine.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Cytarabine.]
[L04AA29, tofacitinib, Cytarabine may increase the immunosuppressive activities of Tofacitinib.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Cytarabine.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Cytarabine.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cytarabine.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Everolimus.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzyl alcohol.]
[L03AA14, lipegfilgrastim, Cytarabine may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ibrutinib.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Cytarabine is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Cytarabine.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Cytarabine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Bezafibrate.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Cytarabine.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cytarabine.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Cytarabine is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Cytarabine.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Cytarabine.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Cytarabine.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Cytarabine.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Acipimox.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mepolizumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixekizumab.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Cytarabine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Brodalumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cytarabine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Cytarabine.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Cytarabine.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Cytarabine.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Cytarabine is combined with Vorinostat.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cytarabine.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cytarabine.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Cytarabine.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Cytarabine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Capsaicin.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Captopril.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Cytarabine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Cytarabine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Baricitinib.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Cytarabine.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cytarabine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Cytarabine.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Cytarabine.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ciprofibrate.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Siponimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ubidecarenone.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Cytarabine.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Risankizumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Upadacitinib.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Cytarabine.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cytarabine.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Cytarabine is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Cytarabine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Diroximel fumarate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Cytarabine.]
[C01BD07, dronedarone, The risk or severity of adverse effects can be increased when Dronedarone is combined with Cytarabine.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cytarabine.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cytarabine.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluprednidene.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Cytarabine is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Stepronin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Cytarabine.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Cytarabine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Cytarabine.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Choline salicylate is combined with Cytarabine.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Etofibrate.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fludarabine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Voclosporin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Cytarabine.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Cytarabine.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Formoterol is combined with Cytarabine.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Cytarabine.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Cytarabine.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Cytarabine is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Anifrolumab.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Cytarabine.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Cytarabine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Cytarabine can be increased when it is combined with Pacritinib.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Cytarabine is combined with Clozapine.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Cytarabine.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Cytarabine.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Cytarabine.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Cytarabine.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Cytarabine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cytarabine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Cytarabine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Cytarabine.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Cytarabine.]
[S01XA18, cyclosporine, Cytarabine may increase the immunosuppressive activities of Cyclosporine.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Rosuvastatin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Cytarabine.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Cytarabine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cytarabine.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cytarabine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Cytarabine.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Cytarabine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cinchocaine.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirarubicin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Difluocortolone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cytarabine.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Pramocaine.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Cytarabine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cytarabine.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Cytarabine.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Cytarabine.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Doxorubicin.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Cytarabine.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Cytarabine.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Cytarabine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Cytarabine.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Cytarabine.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Cytarabine.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Cytarabine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Cytarabine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Cytarabine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cytarabine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Iloprost.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fluvastatin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Cytarabine.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Cytarabine.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Cytarabine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Cytarabine.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Cytarabine.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cytarabine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Cytarabine.]
[J02AX01, flucytosine, The therapeutic efficacy of Flucytosine can be decreased when used in combination with Cytarabine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cytarabine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Cytarabine.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Cytarabine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cytarabine.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cytarabine.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Gemfibrozil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dasatinib.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Cytarabine.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Cytarabine.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Cytarabine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Cytarabine.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Cytarabine.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Cytarabine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Cytarabine.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Cytarabine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Cytarabine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Cytarabine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Cytarabine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxyurea.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Cytarabine.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Cytarabine.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Cytarabine is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ifosfamide.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cytarabine.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cytarabine.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Articaine.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Cytarabine.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Cytarabine.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Cytarabine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Cytarabine.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Cytarabine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Cytarabine.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Cytarabine.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cytarabine.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Cytarabine.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Cytarabine.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Cytarabine.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Cytarabine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Lidocaine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Lomustine.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Cytarabine.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Cytarabine is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cytarabine.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Cytarabine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Cytarabine.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Cytarabine.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Cytarabine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Cytarabine is combined with Melphalan.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Mepivacaine.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Cytarabine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Cytarabine.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cytarabine.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Cytarabine.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cytarabine.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Cytarabine.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cytarabine.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Metoclopramide.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Cytarabine.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Cytarabine.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Minocycline.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cytarabine.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Amiodarone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Cytarabine is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mycophenolic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Raltegravir.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Cytarabine.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Cytarabine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cytarabine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Cytarabine is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Letrozole.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Cytarabine.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Cytarabine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Cytarabine.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Cytarabine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Cytarabine.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Norfloxacin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Cytarabine.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Cytarabine is combined with Rilonacept.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Cytarabine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Cytarabine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Cytarabine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Cytarabine is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Cytarabine.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Cytarabine.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cytarabine.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Phenformin is combined with Cytarabine.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Cytarabine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Cytarabine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Cytarabine.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Cytarabine.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Golimumab.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Cytarabine.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Cytarabine.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Cytarabine.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Cytarabine is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Cytarabine.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Cytarabine.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Pitavastatin.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Cytarabine.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Cytarabine.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Cytarabine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Prilocaine.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Cytarabine.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fenofibrate.]
[G03DA04, progesterone, The risk or severity of adverse effects can be increased when Progesterone is combined with Cytarabine.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Cytarabine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cytarabine.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Cytarabine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Cytarabine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Cytarabine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Cytarabine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Cytarabine.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cytarabine.]
